RecruitingPhase 3ACTRN12614000215628

Efficacy of artesunate 7days therapy for the treatment of uncomplicated Plasmodium falciparum malaria in Pa-an (Mon State) in Myanmar.

A study evaluating the efficacy and safety of artesunate for the treatment of uncomplicated plasmodium falciparum malaria in Pa-An (Mon State) in Myanmar


Sponsor

Clinical Research Unit ( Malaria), Defense Services General Hospital

Enrollment

50 participants

Start Date

Jan 20, 2014

Study Type

Interventional

Conditions

Summary

To study the efficacy of antimalarial drugs in Myanmar


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study is measuring how well a 7-day course of artesunate treats uncomplicated falciparum malaria in Pa-an, Myanmar. Researchers want to confirm whether artesunate is still effective in this region as part of ongoing efforts to monitor drug resistance. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with uncomplicated falciparum malaria by blood test - You have a fever or had one in the past 24 hours - You can swallow oral medications - You are willing to comply with the study schedule You may NOT be eligible if: - You have signs of severe malaria - You are pregnant or breastfeeding - You have a serious underlying illness (heart, kidney, or liver disease, HIV/AIDS) - You are taking medications that interfere with antimalarial drugs - You have previously had your spleen removed - You are allergic to artesunate or related drugs Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The patients will be administered artesunate in oral tablet form (50 mg of artesunate per tablet,) at a dose of 4mg/kg/day for 7 days. Each dose administration will be observed and recorded.

The patients will be administered artesunate in oral tablet form (50 mg of artesunate per tablet,) at a dose of 4mg/kg/day for 7 days. Each dose administration will be observed and recorded.


Locations(1)

Pa-An (Mon state), Myanmar

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614000215628


Related Trials